CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D003324: Coronary Artery Disease NIH

(Synonyms: Coronary Artery D, Coronary Artery Di, Coronary Artery Dise, Coronary Artery Diseas, Coronary Artery Disease)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (12)


Name (Synonyms) Correlation
drug2462 Robot Assisted Percutaneous Cardiovascular Intervention Wiki 0.50
drug2842 Tele-medicine platform Wiki 0.50
drug1465 Intranasal heparin sodium (porcine) Wiki 0.50
drug30 2: No instruction regarding positioning Wiki 0.50
drug2292 QFR Wiki 0.50
drug1472 Intravenous saline injection (Placebo) Wiki 0.50
drug21 1: Prone positioning Wiki 0.50
drug205 Angiography Wiki 0.50
drug3172 allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) Wiki 0.50
drug1458 Intervention group_rehabilitation program Wiki 0.50
drug394 Best Practice Wiki 0.29
drug2928 Tocilizumab Wiki 0.09

Correlated MeSH Terms (16)


Name (Synonyms) Correlation
D003327 Coronary Disease NIH 0.61
D000787 Angina Pectoris NIH 0.50
D023921 Coronary Stenosis NIH 0.50
D009203 Myocardial Ischemia NIH 0.43
D054143 Heart Failure, Systolic NIH 0.35
D007511 Ischemia NIH 0.22
D054058 Acute Coronary Syndrome NIH 0.22
D007676 Kidney Failure, Chronic NIH 0.19
D029424 Pulmonary Disease, Chronic Obstructive NIH 0.18
D006333 Heart Failure NIH 0.17
D008173 Lung Diseases, Obstructive NIH 0.17
D020521 Stroke NIH 0.14
D009369 Neoplasms, NIH 0.10
D002318 Cardiovascular Diseases NIH 0.09
D013577 Syndrome NIH 0.05
D007239 Infection NIH 0.03

Correlated HPO Terms (10)


Name (Synonyms) Correlation
HP:0001677 Coronary artery atherosclerosis HPO 1.00
HP:0005145 Coronary artery stenosis HPO 0.50
HP:0001681 Angina pectoris HPO 0.50
HP:0001658 Myocardial infarction HPO 0.43
HP:0006510 Chronic pulmonary obstruction HPO 0.18
HP:0001635 Congestive heart failure HPO 0.17
HP:0006536 Pulmonary obstruction HPO 0.17
HP:0001297 Stroke HPO 0.14
HP:0002664 Neoplasm HPO 0.10
HP:0001626 Abnormality of the cardiovascular system HPO 0.09

There are 4 clinical trials

Clinical Trials


1 Comparison of Quantitative Flow Ratio Guided and Angiography Guided Percutaneous InterVention in Patients With cORonary Artery Disease (The FAVOR III China Study)

The overall purpose of the FAVOR III China trial is to investigate if a strategy of quantitative flow ratio (QFR)-guided percutaneous coronary intervention (PCI) yields superior clinical outcome and cost-effectiveness compared to a strategy of standard coronary angiography-guided PCI in evaluation of patients with coronary artery disease.

NCT03656848 Coronary Artery Disease Myocardial Ischaemia Coronary Circulation Coronary Stenosis Percutaneous Coronary Intervention Diagnostic Test: QFR Diagnostic Test: Angiography
MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease Coronary Stenosis Ischemia
HPO:Coronary artery atherosclerosis Coronary artery stenosis Myocardial infarction

Primary Outcomes

Description: A composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization

Measure: MACE

Time: 1 year

Secondary Outcomes

Description: all-cause mortality, any spontaneous myocardial infarction and any ischemia-driven revascularization

Measure: MACE excluding peri-procedural MI (Major secondary endpoint)

Time: 1 year

Description: Cardiovascular, non-cardiovascular and undetermined death

Measure: Death

Time: 1 month, 6 months, 1 year, 2 years and 3 years

Description: Target vessel related and non-target vessel related MI

Measure: MI

Time: 1 month, 6 months, 1 year, 2 years and 3 years

Description: The ischemia driven and non-ischemia driven TVR

Measure: Target vessel revascularization (TVR)

Time: 1 month, 6 months, 1 year, 2 years and 3 years

Description: The The ischemia driven and non-ischemia driven Revascularization

Measure: Any coronary artery revascularization

Time: 1 month, 6 months, 1 year, 2 years and 3 years

Description: Definite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2

Measure: Definite or probable stent thrombosis

Time: 1 month, 6 months, 1 year, 2 years and 3 years

Description: PCI strategy changes following QFR and three-dimension quantitative coronary angiography (3D-QCA)

Measure: The PCI strategy changes based on the QFR and 3D-QCA

Time: During the procedure

Description: Costs include direct clinical costs during the initial hospitalization and other resources used, main cardiovascular medication expenses, and outpatient and/or hospitalization expenses associated with MACE.

Measure: Cost during 1-year follow-up

Time: 1 month, 6 months, 1 year

Description: QALYs determined using EuroQol five dimensions questionnaire (EQ-5D) in official Chinese version, to assess the quality of life.

Measure: Quality-adjusted-life-years (QALYs) index

Time: 1 month, 6 months, 1 year

2 Integrated Distance Management Strategy for Patients With Cardiovascular Disease (Ischaemic Coronary Artery Disease, High Blood Pressure, Heart Failure) in the Context of the COVID-19 Pandemic

Management of known patients with cardiovascular disease (in particular the whole spectrum of atherosclerotic ischaemic coronary artery disease, essential hypertension under treatment, and also patients with chronic heart failure under medication) and with other associated chronic pathologies, with obvious effects on the management of the pandemic with modern / distance means (e-Health) of patients at high risk of mortality in contact with coronavirus. Given the Covid-19 Pandemic, all the above complex cardiovascular patients are under the obligation to stay in the house isolated and can no longer come to standard clinical and paraclinical monitoring and control visits. Therefore, a remote management solution (tele-medicine) of these patients must be found. The Investigators endeavour is to create an electronic platform to communicate with these patients and offer solutions for their cardiovascular health issues (including psychological and religious problems due to isolation). The Investigators intend to create this platform for communicating with a patient and stratify their complaints in risk levels. A given specialist will sort and classify their needs on a scale, based on specific algorithms (derived from the clinical European Cardiovascular Guidelines), and generate specific protocols varying from 911 like emergencies to cardiological advices or psychological sessions. These could include medication changing of doses, dietary advices or exercise restrictions. Moreover, in those patients suspected of COVID infection, special assistance should be provided per protocol.

NCT04325867 Angina Pectoris Acute Coronary Syndrome Coronary Syndrome Coronary Artery Disease Angioplasty Stent Restenosis Hypertension Heart Failure, Systolic Depression, Anxiety Covid-19 Isolation, Social Other: Tele-medicine platform
MeSH:Heart Failure Coronary Artery Disease Myocardial Ischemia Coronary Disease Acute Coronary Syndrome Angina Pectoris Heart Failure, Systolic Syndrome Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Angina pectoris Congestive heart failure Coronary artery atherosclerosis Left ventricular dysfunction Myocardial infarction Right ventricular failure

Primary Outcomes

Description: Development of an electronic (e-HEALTH) framework structure for management of patients with known cardiovascular disease in COVID19 pandemic social context

Measure: Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients

Time: 6 months

Description: patients come into direct contact with the case coordinator, who provides ongoing assistance, including for connecting to devices that ensure real-time data transmission and directing to specialist teams that establish stage diagnosis and management / therapy behavior (including adjustment). doses, decisions to discontinue medication or to add medication);

Measure: Number of patients included in this platform

Time: 6 months

Secondary Outcomes

Description: Will be the number of sessions per patient multiplied with the number of patients included

Measure: Number of consultations/sessions given

Time: 6 months

3 Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2: An Open-Labeled, Randomized Phase 3 Trial

This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.

NCT04361552 Cerebrovascular Accident Chronic Obstructive Pulmonary Disease Chronic Renal Failure Coronary Artery Disease Diabetes Mellitus Malignant Neoplasm SARS Coronavirus 2 Infection Other: Best Practice Biological: Tocilizumab
MeSH:Infection Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Stroke Kidney Failure, Chronic Coronary Artery Disease Neoplasms
HPO:Chronic pulmonary obstruction Coronary artery atherosclerosis Neoplasm Pulmonary obstruction Stroke

Primary Outcomes

Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.

Measure: 7-day length of invasive mechanical ventilation (MV)

Time: Up to 7 days

Description: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: 30-day mortality rate

Time: Up to 30-day after randomization

Secondary Outcomes

Description: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of intensive care (ICU) transfer

Time: Up to 2 years

Description: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of invasive mechanical ventilation

Time: Up to 2 years

Description: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.

Measure: Rate of tracheostomy

Time: Up to 2 years

Description: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test

Measure: Length of ICU stay

Time: Up to 2 years

Measure: Length of hospital stay

Time: Up 2 years

4 Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses

Percutaneous cardiovascular intervention procedures (e.g. coronary angioplasty, peripheral artery angioplasty) must be performed in person, requiring the physical presence of one or more medical, nursing and technical professionals. The control of catheters and interventional materials is performed manually, with the operator positioned next to the patient. This context results in potential for reciprocal exposure to exhaled air, both for the professionals involved and for the patient, with an inherent risk of aerial contamination. It is important to note that interventional procedures are often performed on an urgent or emergency basis (e.g. myocardial infarction), without the possibility of postponement or postponement. The recent robot-assisted cardiovascular intervention makes it possible to modify this scenario by allowing the procedure to be performed effectively and safely in a position far from the patient. In an environment with high potential for contamination, mainly related to the current pandemic caused by the COVID-19 virus, may prove to be a tactic to expand hospital security. It is in this sense that the present pilot proposal is inserted, which, ultimately, aims to evaluate the potential of robotic intervention as a strategy to reduce exposure to exhaled air of patients and professionals during the intervention procedure.

NCT04379453 Coronary Artery Disease Procedure: Robot Assisted Percutaneous Cardiovascular Intervention
MeSH:Coronary Artery Disease Myocardial Ischemia Coronary Disease
HPO:Coronary artery atherosclerosis Myocardial infarction

Primary Outcomes

Description: (arterial dilation with residual lesion <50% at angiography and normal anterograde flow)

Measure: Successful cardiovascular intervention

Time: Until the end of the procedure

Measure: Performed with the professional team positioned at> 2 meters from the patient for at least 50% of the duration of the intervention

Time: Until the end of the procedure

Measure: absence of fatal complications caused by the procedure or acute non-fatal vessel occlusion during index admission

Time: Until the end of the procedure


HPO Nodes